Clinical, immunological, ultrastructural, and cytogenetic studies in black patients with adult T-cell leukemia/lymphoma. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Clinical, immunological, ultrastructural, and cytogenetic studies in black patients with adult T-cell leukemia/lymphoma.

Princess Takamatsu Symp. 1984;15:59-70. Unique Identifier : AIDSLINE MED/86111577
Matutes E; Brito-Babapulle V; Catovsky D


Abstract: We describe studies in 14 black patients with adult T-cell leukemia/lymphoma (ATLL) born in the Caribbean (13) and west Africa (1). Lymphadenopathy, hypercalcemia, and a leukemic blood picture were seen in the majority. The clinical course was short with a median survival of 5 months. Serum antibodies to human T-cell leukemia virus (HTLV) were detected in all the 10 cases investigated. Marker studies showed a mature (post-thymic) T4+ T-cell phenotype. Functional studies in 3 cases demonstrated that the cells did not provide help but rather suppressed B-cell differentiation. Cells from 2 cases of T4+ prolymphocytic leukemia (T-PLL) were shown to have helper function. Type C viral particles were identified by electron microscopy (EM) on cultured cells from 4 ATLL patients and these were shown to react with the monoclonal antibody (McAb) to the HTLV proteins p19 and p24. Such findings were not observed in HTLV negative T-cell leukemias except for cells of a T-PLL which showed evidence of budding and extracellular release of C-type particles after 5 days culture with phytohemagglutinin (PHA). A close association between the localization of the receptor for T-cell growth factor, demonstrated by McAb anti-Tac, and areas of the cell membrane showing release of HTLV viral particles was documented at EM level by the immunogold method. This technique also demonstrated the specific binding of anti-p19 to HTLV. Cytogenetic studies on PHA stimulated cultures from 2 ATLL revealed trisomy for 7q and this was also observed in 1 of 2 T-PLL and 2 of 4 Sezary syndrome cases. The clinical, morphological, immunological, and cytogenetic features of ATLL in black patients diagnosed in the U.K. are identical to those reported from Japan and the U.S.A. There is also strong evidence that the disease is caused by HTLV-I.
Keywords: Adult Antibodies, Viral/ANALYSIS Antigens, Surface/ANALYSIS Chromosome Aberrations Female Human HTLV-BLV Viruses/IMMUNOLOGY/ISOLATION & PURIF Leukemia/GENETICS/*IMMUNOLOGY/MICROBIOLOGY Lymphoma/GENETICS/*IMMUNOLOGY/MICROBIOLOGY Male Middle Age Negroid Race Receptors, Immunologic/ANALYSIS Support, Non-U.S. Gov't JOURNAL ARTICLE REVIEW

KWDadultantibodies,viral/analysisantigens,surface/analysischromosomeaberrationsfemalehumanhtlv-blvviruses/immunology/isolation&purifleukemia/genetics/KWDimmunology/microbiologylymphoma/genetics/KWDimmunology/microbiologymalemiddleagenegroidracereceptors,immunologic/analysissupport,non-uKWDsKWDgov'tjournalarticlereview
860530
M8650212


Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .